TITLE

Healthcare utilization of patients accessing an African national treatment program

AUTHOR(S)
Harling, Guy; Orrell, Catherine; Wood, Robin
PUB. DATE
January 2007
SOURCE
BMC Health Services Research;2007, Vol. 7, p80
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The roll-out of antiretroviral therapy (ART) in Africa will have significant resource implications arising from its impact on demand for healthcare services. Existing studies of healthcare utilization on HAART have been conducted in the developed world, where HAART is commenced when HIV illness is less advanced. Methods: This paper describes healthcare utilization from program entry by treatment-naïve patients in a peri- urban settlement in South Africa. Treatment criteria included a CD4 cell count <200 cells/μl or an AIDS-defining illness. Data on health service utilization were collected retrospectively from the primary-care clinic and secondary and tertiary referral hospitals. Hospital visits were reviewed to determine the clinical reason for each visit. Results: 212 patients were followed for a median of 490 days. Outpatient visits per 100 patient years of observation (PYO), excluding scheduled primary-care follow-up, fell from 596 immediately prior to ART to 334 in the first 48 weeks on therapy and 245 thereafter. Total inpatient time fell from 2,549 days per 100 PYO pre-ART to 476 in the first 48 weeks on therapy and 73 thereafter. This fall in healthcare utilization occurred at every level of care. The greatest causes of utilization were tuberculosis, cryptococcal meningitis, HIV-related neoplasms and adverse reactions to stavudine. After 48 weeks on ART demand reverted to primarily non-HIV-related causes. Conclusion: Utilization of both inpatient and outpatient hospital services fell significantly after commencement of ART for South African patients in the public sector, with inpatient demand falling fastest. Earlier initiation might reduce early on-ART utilization rates.
ACCESSION #
29324496

 

Related Articles

  • Clinical Management of Treatment- Experienced, HIV/AIDS Patients in the Combination Antiretroviral Therapy Era. Boyd, Mark A.; Hill, Andrew M. // PharmacoEconomics;2010 Supplement, Vol. 28, p17 

    Despite the success of combination antiretroviral therapy (ART) in improving clinical outcomes, treatment failure remains a significant challenge, particularly for highly treatment-experienced patients. This review evaluates current issues in the management of HIV-infected, treatment-experienced...

  • Highly Active Antiretroviral Therapy Use and HIV Transmission Risk Behaviors Among Individuals Who Are HIV Infected and Were Recently Released From Jail. Clements-Nolle, Kristen; Marx, Rani; Pendo, Michael; Loughran, Eileen; Estes, Milton; Katz, Mitchell // American Journal of Public Health;Apr2008, Vol. 98 Issue 4, p661 

    We evaluated highly active antiretroviral therapy (HAART) use and risk behaviors among 177 inmates who were HIV infected and were released and reincarcerated in San Francisco, Calif, jails over a 12-month period. During the month preceding reincarceration, HIV transmission risk behaviors were...

  • A Review of Economic Evaluations of Darunavir Boosted by Low-Dose Ritonavir in Treatment-Experienced Persons Living with HIV Infection. Mauskopf, Josephine; Annemans, Lieven; Hill, Andrew M.; Smets, Erik // PharmacoEconomics;2010 Supplement, Vol. 28, p1 

    Darunavir boosted by low-dose ritonavir (DRV/r), at a daily dose of 600/100mg twice a day (bid), has been shown to be superior to alternative highly active antiretroviral therapy (HAART) regimens for the management of treatment-experienced, HIV-infected adults in the phase IIb POWER trials and...

  • Early antiretroviral therapy: The pendulum shifts again. Saple, D. G.; Jindal, Saurabh; Vaidya, Satish // Indian Journal of Dermatology, Venereology & Leprology;May/Jun2008, Vol. 74 Issue 3, p189 

    The article comments on the pros and cons of earlier initiation of highly active antiretroviral therapy (HAART) for the management of HIV infection. According to the authors, one crucial issue about when to start ART involves the capacity of the healthcare system to provide uninterrupted access...

  • Association of Antiretroviral Therapy Adherence and Health Care Costs. Nachega, Jean B.; Leisegang, Rory; Bishai, David; Hoang Nguyen; Hislop, Michael; Cleary, Susan; Regensberg, Leon; Maartens, Gary // Annals of Internal Medicine;1/5/2010, Vol. 152 Issue 1, p18 

    Background: Antiretroviral therapy (ART) adherence predicts HIV disease progression and survival, but its effect on direct health care costs is unclear. Objective: To determine the effect of ART adherence on direct health care costs among adults in a resource-limited setting. Design: Cohort...

  • The Macroeconomic Consequences of Renouncing to Universal Access to Antiretroviral Treatment for HIV in Africa: A Micro-Simulation Model. Ventelou, Bruno; Arrighi, Yves; Greener, Robert; Lamontagne, Erik; Carrieri, Patrizia; Moatti, Jean-Paul // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    Aim: Previous economic literature on the cost-effectiveness of antiretroviral treatment (ART) programs has been mainly focused on the microeconomic consequences of alternative use of resources devoted to the fight against the HIV pandemic. We rather aim at forecasting the consequences of...

  • The Macroeconomic Consequences of Renouncing to Universal Access to Antiretroviral Treatment for HIV in Africa: A Micro-Simulation Model. Ventelou, Bruno; Arrighi, Yves; Greener, Robert; Lamontagne, Erik; Carrieri, Patrizia; Moatti, Jean-Paul // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    Aim: Previous economic literature on the cost-effectiveness of antiretroviral treatment (ART) programs has been mainly focused on the microeconomic consequences of alternative use of resources devoted to the fight against the HIV pandemic. We rather aim at forecasting the consequences of...

  • People with AIDS (PWA) Since Highly Active Antiretroviral Therapy, 1996. Dunbar, Deanne // Journal of Medical Humanities;Jun2011, Vol. 32 Issue 2, p115 

    lthough clarity about HIV transmission biology and effective therapy should mean that an AIDS diagnosis is more socially acceptable today, for some groups the cultural stigma of HIV infection has changed little in the last 30 years. This paper will examine why representations of HIV-positive gay...

  • Review of antiretroviral agents for the treatment of HIV infection. Stanic, Anela; Grana, Julie C. // Formulary;Feb2009, Vol. 44 Issue 2, p47 

    Research into the treatment of HIV infection has resulted in the development of 5 antiretroviral (ARV) drug classes: entry inhibitors, including fusion inhibitors and chemokine coreceptor (CCR) inhibitors; nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs); non-nucleoside reverse...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics